These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37501501)

  • 1. Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases.
    Iriyama C; Murate K; Iba S; Okamoto A; Goto N; Yamamoto H; Kato T; Mihara K; Miyama T; Hattori K; Kajiya R; Okamoto M; Mizutani Y; Yamada S; Tsukamoto T; Hirose Y; Mutoh T; Watanabe H; Tomita A
    Cancer Med; 2023 Aug; 12(16):16972-16984. PubMed ID: 37501501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.
    Yamagishi Y; Sasaki N; Nakano Y; Matushita Y; Omura T; Shimizu S; Saito K; Kobayashi K; Narita Y; Kondo A; Shiokawa Y; Nagane M; Ichimura K
    Cancer Sci; 2021 Nov; 112(11):4702-4710. PubMed ID: 34523186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
    Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M
    BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy for CNS lymphoma: CSF exosomes and CSF exosomal miR-15a, miR-21, miR-155, miR-210, and miR-19b are promising biomarkers for diagnosis.
    Hatiboglu MA; Karacam B; Khan I; Akdur K; Elbasan EB; Mahfooz S; Seyithanoglu MH; Cetin G; Papaker MG; Oztanir MN
    Mol Biol Rep; 2024 Oct; 51(1):1035. PubMed ID: 39361107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
    Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
    J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid.
    Hiemcke-Jiwa LS; Minnema MC; Radersma-van Loon JH; Jiwa NM; de Boer M; Leguit RJ; de Weger RA; Huibers MMH
    Hematol Oncol; 2018 Apr; 36(2):429-435. PubMed ID: 29210102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
    Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
    BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of the
    Zorofchian S; Lu G; Zhu JJ; Duose DY; Windham J; Esquenazi Y; Ballester LY
    Front Oncol; 2018; 8():382. PubMed ID: 30294590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.
    Strehlow F; Bauer S; Martus P; Weller M; Roth P; Schlegel U; Seidel S; Scheibenbogen C; Korfel A; Kreher S
    J Neurooncol; 2016 Aug; 129(1):165-71. PubMed ID: 27294357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.
    Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Bromberg JEC; Nierkens S; Jiwa NM; Minnema MC; Huibers MMH
    Br J Haematol; 2019 Jun; 185(5):974-977. PubMed ID: 30408153
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Kitano Y; Maeda S; Motomura K; Aoki K; Takeuchi K; Nagata Y; Hattori H; Tsujiuchi T; Motomura A; Nishikawa T; Kibe Y; Shinjo K; Kondo Y; Saito R
    Cancer Sci; 2023 Jun; 114(6):2544-2551. PubMed ID: 36859777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma.
    Ikeguchi R; Shimizu Y; Shimizu S; Kitagawa K
    Mult Scler; 2018 Aug; 24(9):1212-1223. PubMed ID: 28657431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Detection Rate of
    Watanabe J; Natsumeda M; Okada M; Kobayashi D; Kanemaru Y; Tsukamoto Y; Oishi M; Kakita A; Fujii Y
    JCO Precis Oncol; 2019 Dec; 3():1-13. PubMed ID: 35100686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of pediatric central nervous system tumors using methylation profiling of cfDNA from cerebrospinal fluid.
    Cornelli L; Van Paemel R; Ferro Dos Santos MR; Roelandt S; Willems L; Vandersteene J; Baert E; Mus LM; Van Roy N; De Wilde B; De Preter K
    Clin Epigenetics; 2024 Jul; 16(1):87. PubMed ID: 38970137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of serum and cerebrospinal fluid MMP-9, CCL2 and sVCAM-1 in leukemia CNS metastasis.
    Si MY; Fan ZC; Li YZ; Chang XL; Xie QD; Jiao XY
    J Neurooncol; 2015 Apr; 122(2):229-44. PubMed ID: 25630624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of CSF biological investigations for CNS lymphoma diagnosis.
    Armand M; Costopoulos M; Osman J; Tarfi S; Houillier C; Choquet S; Agnelo H; Bonnemye P; Ronez E; Settegrana C; Soussain C; Hoang-Xuan K; Le Garff-Tavernier M; Davi F
    Am J Hematol; 2019 Oct; 94(10):1123-1131. PubMed ID: 31328307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
    Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive role of cerebrospinal fluid hydrogen sulfide in central nervous system leukemia.
    DU SX; Xiao J; Guan F; Sun LM; Wu WS; Tang H; DU JB; Tang CS; Jin HF
    Chin Med J (Engl); 2011 Nov; 124(21):3450-4. PubMed ID: 22340157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma.
    Bravetti C; Degaud M; Armand M; Sourdeau E; Mokhtari K; Maloum K; Osman J; Verrier P; Houillier C; Roos-Weil D; Soussain C; Choquet S; Hoang-Xuan K; Le Garff-Tavernier M; Denis JA; Davi F
    Br J Haematol; 2023 Jun; 201(6):1088-1096. PubMed ID: 36941788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.